Spyre Therapeutics reports Phase 2 SKYWAY RA data for SPY072 shows statistically significant benefit vs placebo
SYRE•Development outlook
Effect size missed Spyre’s threshold to advance SPY072 as an RA monotherapy, shifting emphasis toward other indications and combinations.
Further topline readouts are scheduled for psoriatic arthritis and axial spondyloarthritis in Q4 2026, with a hidradenitis suppurativa combination readout in late 2027 or early 2028.
Phase 2 SKYWAY rheumatoid arthritis results
Spyre Therapeutics reported topline Phase 2 SKYWAY rheumatoid arthritis sub-study results for TL1A antibody SPY072.
Both doses delivered statistically significant benefits versus placebo on at least one key clinical outcome, supporting proof-of-mechanism in RA.
Safety appeared comparable to placebo, reinforcing tolerability consistent with the TL1A class.
